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1. Introduction 
Two major screening models are currently available in the world for colorectal cancer: 
systematic screening and opportunistic screening. Systematic screening covers all segments 
of the population in a certain area and requires the participation of specialized institutions 
and professionals as well as huge financial support. It is a population-based active 
screening. Opportunistic screening targets those who seek medical treatment and screens for 
disease of interest during patients’ treatment or examination. Compared with systematic 
screening, opportunistic screening has the advantages of good compliance and no need for 
additional examination with slightly increased cost. The key to opportunistic screening for 
colorectal cancer is to identify the population at high risk for colorectal cancer and 
determine who need such screening. The criteria for identification of high-risk population 
for colorectal cancer include mainly family history, personal history, laboratory testing, and 
age: ᬅ hereditary non-polyposis colorectal cancer (HNPCC) family members aged ≥ 10 
years; ᬆ individuals with first-degree relatives with familial polyposis aged ≥10 years; ᬇ 
individuals with first-degree relatives with colorectal cancer and aged ≥ (the age of the 
diagnosis of colorectal cancer in the affected relatives minus 10 years ) (i.e. first-degree 
relatives who are 10 years younger than a colorectal cancer patient are at high risk for the 
cancer. For example, the first-degree relatives aged 50 years or older of a 60-year-old 
colorectal cancer patient are high-risk population for colorectal cancer.); ᬈ previous history 
of colorectal cancer or colorectal adenoma; ᬉ ulcerative colitis or Crohn’s disease unhealed 
for more than 10 years; ᬊ history of biliary tract disease or cholecystectomy for more than 
10 years; ᬋ history of lower abdominal radiotherapy for more than 10 years; ᬌ history of 
chronic schistosomiasis in the colon; ᬍ history of chronic appendicitis; ᬎ unexplained 
positive fecal occult blood test; ⑪ unexplained elevated serum CEA level; and ⑫ age of 50 
years and older. 
Development of screening models for colorectal cancer depends on disease risk stratification 
of individuals in the population. The risk of colorectal cancer development in individuals in 
a natural population with no symptoms of colorectal cancer is stratified into four levels: ᬅ 
Level III high risk. Individuals in this subgroup have the highest risk and about 5% of 
colorectal cancer cases occur in this population, who should undergo screening every 3 
months to 1 year. ᬆ Level II high risk. About 15-20% of colorectal cancer cases occur in this 
population, who should undergo screening every 1 to 5 years. ᬇ Level I high risk. About 
70% to 80% of colorectal cancer cases occur in this population, who should undergo 
screening at a frequency of 5 to 10 years. Stratifying the population at high risk for colorectal 
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cancer into levels I, II, III high-risk subgroups will help choose screening methods and the 
timing of screening. ᬈ Low-risk subgroup. This population is at low risk for colorectal 
cancer and no screening is thus needed. 
Major screening methods for colorectal cancer include digital rectal examination, fecal occult 
blood test, sigmoidoscopy, full colonoscopy and genetic testing. Full colonoscopy can serve 
as the preferred modality for opportunistic screening for colorectal cancer. If full 
colonoscopy is performed only after the discovery of distal colorectal tumor via 
sigmoidoscopy, there will be a missed diagnosis rate of 72.0%. 
Our study shows that by performing opportunistic screening among high-risk populations, 
the average direct cost for each detected case of colorectal cancer is about 50,000 RMB yuan, 
four times less than the cost of systematic screening. For each detected case of colorectal 
tumor (cancer and adenoma combined), the direct cost of opportunistic screening on 
average is 2,000 RMB yuan. These data show favorable cost-effectiveness of opportunistic 
screening for colorectal cancer. In addition, of the colorectal cancers detected among high-
risk populations, the proportion of colorectal cancers staged at Duke’s A and B is 45% and 
33% respectively. In contrast, of the colorectal cancers detected among symptomatic 
hospital-visiting patients, the proportion of colorectal cancers staged at Duke’s A and B is 
4% and 29%, respectively. Previous research has established that the 5-year survival rate 
following surgery of Dukes’ A colorectal cancer can reach as high as 90%, which 
demonstrates the good social benefit of opportunistic screening. 
Worldwide, the incidence rate of colorectal cancer ranks only after lung cancer and breast 
cancer. Overall, colorectal cancer accounts for 9% and 10% of malignant tumors in men and 
women respectively. Colorectal cancer thus poses a serous public health problem and 
increases greatly the burden of disease. In recent two decades, the incidence and mortality 
rates of colorectal cancer in the world increase significantly, with the incidence rate 
increasing from an annual average of about 2% to 6.4% and the average mortality rate 
increasing by 3.3% annually. 
Currently, the incidence rate of colorectal cancer in China is 16.3/100,000 for men, 
12.2/100,000 for women, and 14.2/100,000 for the whole population. The mortality rate of 
colorectal cancer in China is 8.0/100,000 for men, 5.9/100,000 for women, and 6.9/100,000 
for the whole population. In recent years, with changes in lifestyle, dietary structure, and 
environment in China, the incidence and mortality rates of colorectal cancer are on the rise 
and its incidence rate ranks the fourth in malignant tumors. Its incidence rates in the 1990s 
increased by 31.9% in urban areas and 8.5% in rural areas as compared with the incidence 
rates in the 1990s. It is expected that colorectal cancer cases will be nearly doubled by 2030, 
with 400,086 new cases and 211,714 deaths. 
Because colorectal cancer often presents no symptoms in the early stage, patients do not 
seek timely medical treatment. By the time clinical symptoms of colorectal cancer appear, 
their condition will usually have progressed to intermediate or advanced stages which are 
associated with increased disease burden and poor prognosis. Previous studies suggest that 
at least 80% of colorectal cancers derive from colorectal adenoma and that the transition 
from colorectal adenoma to colorectal cancer lasts over 5 years, with an average of 10 to 15 
years, which makes early detection of lesions through screening possible. Considerable 
evidence based on research has confirmed that colorectal cancer screening in the population 
can identify precancerous disease and precancerous lesions of colorectal cancer as well as 
early colorectal cancer. Treatment can be prescribed, thereby reducing the incidence and 
mortality rates of colorectal cancer, and economic burden of colorectal cancer. 
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Population at risk of colorectal cancer has a likelihood of colorectal cancer development 2 to 
4 times higher than the general population. High-risk population screening is an important 
part of secondary prevention of colorectal cancer. The focus of current medical model is 
shifting towards "early prevention". Strengthening the screening of colorectal cancer will 
contribute to "early prevention" and early diagnosis and early treatment, and will ultimately 
improve 5-year survival rate of colorectal cancer patients. 
1.1 Overview  
Two major screening models are currently available for colorectal cancer: systematic 
screening and opportunistic screening. Systematic screening covers all segments of the 
population in a certain area and requires the participation of specialized institutions and 
professionals as well as huge financial support. It is a population-based active screening. 
Opportunistic screening targets those who seek medical treatment and screens for disease of 
interest during patients’ treatment or examination. Compared with systematic screening, 
opportunistic screening has the advantages of good compliance and no need for additional 
examination with slightly increased cost. Therefore, opportunistic screening among the 
population at high risk of colorectal cancer is feasible and also of great significance for early 
diagnosis of colorectal cancer. Opportunistic screening can be performed at outpatient 
departments or health examination centers, with no need of special financial support or 
additional personnel. Hence, it is individual-based passive screening. Our study shows that 
for each detected case of colorectal cancer, the average direct cost of systematic screening is 
about four times as much as that of opportunistic screening. 
The main targets of opportunistic screening can be divided into three categories: ᬅ 
individuals seeking health examination in the hospitals (community or health examination 
centers); ᬆ individuals seeking medical treatment for disease other than colorectal cancer 
but having high risk factors for colorectal cancer (individuals present no clinical 
manifestations of colorectal tumors but have definite positive family history or personal 
history); ᬇ outpatients with no symptoms of colorectal cancer. 
2. Definition of high-risk population for colorectal cancer 
High-risk population refers to a group of individuals at high risk of a certain disease. 
Currently there is no unified definition of high-risk population for colorectal cancer in the 
international community. In general, identification of high-risk population for colorectal 
cancer is conducted by integrating family history, personal history, laboratory tests and 
age.  
Family history  
1. hereditary non-adenomatous colorectal cancer (HNPCC) family members aged ≥ 10 
years;  
2. first-degree relatives with familial polyposis aged ≥ 10 years;  
3. individuals with first-degree relatives with colorectal cancer and aged ≥ (the age of the 
diagnosis of colorectal cancer in the affected relatives minus 10 years ) (i.e. first-degree 
relatives 10 years younger than the colorectal cancer patient are high-risk population. 
For example, the first-degree relatives aged 50 years or older of a 60-year-old colorectal 
cancer patient are high-risk population for colorectal cancer.);  
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Personal History  
4. previous history of colorectal cancer or colorectal adenoma;  
5. ulcerative colitis or Crohn’s disease unhealed for more than 10 years;  
6. history of biliary tract disease or cholecystectomy for more than 10 years;  
7. history of lower abdominal radiotherapy for more than 10 years;  
8. history of chronic colonic schistosomiasis;  
9. history of chronic appendicitis;  
Laboratory tests 
10. unexplained positive fecal occult blood test;  
11. unexplained elevated serum CEA level;  
Advanced age  
12. age of 50 years and older.  
Subjects presenting any one or more of the following symptoms are symptomatic of 
colorectal cancer and diagnostic testing is indicated. ᬅaltered bowel habits (diarrhea, 
constipation, etc.); ᬆ stool changes (thinning stool, blood stool, mucus stool, etc.); ᬇ 
tenesmus (feeling of unsatisfied defecation); ᬈabdominal mass; ᬉintestinal obstruction; ᬊ 
unexplained lower abdominal discomfort or abdominal pain; ᬋunexplained anemia; ᬌ 
unexplained weight loss or systemic cancer symptoms (such as fatigue, fever, etc.). 
Subjects less than 50 years of age who do not meet the criteria of colorectal cancer high-risk 
populations and present no symptoms of colorectal cancer have low risk of colorectal cancer 
development and no screening is needed. If screening is required by an individual, fecal 
occult blood test in conjunction with colonoscopy can be employed. 
3. Risk stratification of high-risk colorectal cancer populations  
To achieve good cost-effectiveness and feasibility, screening can be performed in the 
population with high prevalence. Usually there are three ways of looking for population 
with high prevalence: ᬅ questionnaire-based search for high-risk groups. High-risk 
populations are more likely to develop a certain disease than asymptomatic populations; ᬆ 
conducting screening among a group of subjects with a particular clinical symptom or who 
are positive for a certain test; ᬇ conducting opportunistic screening at outpatient 
departments of hospitals or community medical centers. No matter which method is chosen, 
risk stratification of individuals is the first step of screening. On the basis of previous studies 
at home and abroad, we stratify the risk of asymptomatic individuals developing colorectal 
cancer into four levels. 1. Level III high risk. Individuals in this subgroup have the highest 
risk, who include ᬅHNPCC family members aged ≥ 10 years; ᬆ individuals with first-
degree relatives with familial polyposis aged ≥10 years; ᬇ ulcerative colitis or Crohns 
disease unhealed for more than 10 years. About 5% of colorectal cancer cases occur in the 
level III high-risk population. 2. Level II high risk. Subjects at level II high risk of colorectal 
cancer include: ᬅ individuals with history of colorectal cancer; ᬆ individuals with history 
of colorectal adenoma; ᬇ individuals with first-degree relatives with colorectal cancer and 
aged ≥ (the age of the affected relatives minus 10 years); ᬈ individuals with first-degree 
relatives with colorectal adenoma and aged ≥ (the age of the affected relatives minus 10 
years );ᬉ individuals with cholecystectomy performed more than 10 years ago; ᬊindividuals with history of lower abdominal radiotherapy for more than 10 years；ᬋ 
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individuals with chronic colonic schistosomiasis；ᬌ individuals with chronic 
appendicitis。About 15-20% of colorectal cancer cases occur in the level II high-risk 
population. 3. Level I high risk. Individuals at this risk level refer to a group of subjects who 
have an age of 50 years and older, present no colorectal cancer symptoms, and do not meet 
the criteria of levels II and III high-risk populations. About 70% to 80% of colorectal cancer 
cases occur in the level I high-risk population. Stratifying the population at high risk for 
colorectal cancer into levels I, II, III high-risk subgroups will help choose screening methods 
and the timing of screening. 4. Low-risk subgroup. Individuals at this risk level refer to a 
group of subjects under 50 years who have no symptoms of colorectal cancer and do not 
meet the criteria of levels II and III high-risk populations. This population is at low risk of 
colorectal cancer and no screening is thus needed. 
4. Strategies of opportunistic screening for colorectal cancer  
A complete colorectal cancer screening program should include determination of the 
population to be screened, the choice of screening methods, screening monitoring of 
different populations. There are various methods available for colorectal cancer screening 
and there is no generally accepted consensus worldwide as to which method is to be chosen 
and what program is most effective. American Cancer Society (ACS), United States 
Preventive Service Task Force (USPSTF), US Multisociety Task Force On Colorectal Cancer, 
American Society for Gastrointesinal Endoscopy (ASGE) and National Comprehensive 
Cancer Network (NCCN) have issued their own colorectal cancer screening guidelines [2-5]. 
The United Kingdom, Canada, and China also have developed their own screening 
guidelines. On the basis of these aforementioned guidelines, we developed an opportunistic 
screening program for colorectal cancer. 
 
Risk stratification Starting time of 
screening 
Frequency of colonoscopy 
I. Level I high risk   
1. More than 50 years old 50 years old Every 10 years
II. Level II high risk  
2. Family history of colorectal 
cancer 
 
ķFirst-degree relatives 
developing colorectal  
cancer at an age <60 years 
40 years old or 10 years 
earlier than the age of  
onset of the youngest 
affected relative
Every 3-5 years if the first 
colonoscopy is normal  
ĸFirst-degree relatives 
developing colorectal 
 cancer at an age ≥60 years
40 years old Every 3-5 years if the first 
colonoscopy is normal 
3. Family history colorectal 
adenoma 
 
ķFirst-degree relatives 
developing colorectal  
adenoma at an age <60 years 
40 years old or 10 years 
earlier than the age of 
onset of the youngest 
affected relative
Every 5 years if the first  
colonoscopy is normal 
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Risk stratification Starting time of 
screening 
Frequency of colonoscopy 
ĸFirst-degree relatives 
developing colorectal 
adenoma at an age ≥60 years 
Individually determined Every 10 years if the first colonoscopy 
is normal 
4. Personal history of 
colorectal cancer 
ķPersonal history of colon 
cancer 
One year after surgical 
resection of the cancer 
Re-examination at the 3rd year if the 
first one is normal and later every 5 
years 
ĸPersonal history of rectal 
cancer 
One year after surgical 
resection of the cancer 
 Re-examination at the 4th year if the 
first one is normal and later every 5 
years 
Every 3-6 months in the first 2-3 years 
following low resection when no 
pelvic radiotherapy or mesorectal 
excision is performed 
5. Personal history of 
colorectal adenoma 
ķColonic adenomas ≤2, 
diameter <1cm and mild 
atypical hyperplasia 
Not earlier than 5 years 
after surgery 
 
Every 5 years 
ĸAdvanced tumors or 
adenomas >3  
One year after surgery Every 3 years 
ĹVillous adenoma
accompanied by possible 
incomplete excision
Within 2-6 months after 
surgery 
Every 3 years 
6. Cholecystectomy
performed more than  
10 years ago
At the time of knowledge Every 5 years 
7. History of lower abdominal 
radiotherapy performed 
more than 10 years ago
At the time of knowledge Every 5 years 
8. Chronic colonic 
schistosomiasis
At the time of knowledge Every 5 years 
9. Chronic appendicitis At the time of knowledge Every 5 years 
III. Level III high risk   
HNPCC family history 20-25 years old or 10 years 
earlier than the age of 
onset of the youngest 
family member 
Every 1-2 years and every 1 year after 
40 years old 
FAP family history 
ķGenetic test of FAP  
proband (+) 
  
Genetic test of FAP  
relatives (+) 
10-12 years old Every 1 year and, if no polyp is 
present, every 1 year until the age of 
40 years. Then every 3-5 years. 
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Risk stratification Starting time of 
screening 
Frequency of colonoscopy 
Genetic test of FAP relatives (-) 10-12 years old Every 7-10 years until the age of 40 
years. Then every 5 years. 
ĸGenetic test of FAP 
proband (-) 
 
10-12 years old Every 1 year and, if no polyp is 
present, every 1 year until the age of 
40 years.Thereafter, every 3-5 years. 
Inflammatory bowel disease 
(ulcerative colitis or extensive 
Crohn's colitis) 
10 years after onset Every 1-2 years 
Note: HNPCC: hereditary non-polyposis colorectal cancer; FAP: familial adenomatous polyposis  
Table 1. Opportunistic screening programs for colorectal cancer 
5. Screening methods and benefits  
Screening methods for colorectal cancer mainly include digital rectal examination, fecal 
occult blood test, sigmoidoscopy, full colonoscopy and genetic testing. We recommend full 
colonoscopy as the preferred examination for opportunistic screening of the population at 
high risk of colorectal cancer. This recommendation is based on the following reasons. First, 
colonoscopy is needed to reach a definite diagnosis when other screening methods are 
positive. Second, colonoscopy is the only screening modality capable of both diagnosis and 
treatment. Third, if colonoscopy is performed only after distal colon cancer is found with 
sigmoidoscopy, there will be a missed diagnosis rate of 72.0%. If full colonoscopy cannot be 
used as the examination of choice for screening subjects, immunoassay fecal occult blood 
test can be performed daily for three consecutive days and, if positive, full colonoscopy can 
be then conducted.  
A total of 3704 high-risk subjects were screened using full colonoscopy and 807 patients 
with colorectal tumors were identified, including 11 with colorectal cancer and 796 with 
colorectal adenomatous polyps, with a detection rate of colorectal tumor 22.8% and a 
detection rate of colorectal cancer 0.3%. Compared with the diagnosis of the 2675 subjects 
with colorectal cancer symptoms who sought medical help at the gastrointestinal 
departments, Dukes’ A and B stage colorectal cancers accounted for 45% and 33% (78% 
combined) of the colorectal cancers detected in the high-risk population respectively 
whereas Dukes’ A and B stage colorectal cancers accounted for 4% and 29% (33% combined) 
of the colorectal cancers detected in the symptomatic subjects seeking medical help at 
hospitals. This indicates that screening among high-risk population is an effective way for 
early detection of colorectal cancer. Previous research has established that the 5-year 
survival rate of Dukes’ A colorectal cancer following surgery can reach as high as 90%, 
showing colorectal cancer screening will greatly enhance the survival rate of patients and 
yield good social benefits.  
Our series of studies have shown that for every detected case of colorectal cancer, the 
average direct cost of systematic screening is 200,000 RMB yuan whereas the average direct 
cost of opportunistic screening is only about 50,000 RMB yuan, 4 times less than the cost of 
systematic screening. For each detected case of colorectal tumor (cancer and adenoma), 
opportunistic screening costs 2,000 RMB yuan on average. This shows the great economic 
benefit of opportunistic screening for colorectal cancer. 
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6. Issues and suggestions  
Screening should cover more of the target population. The biggest drawback of opportunistic 
screening is that only those who seek medical help at hospitals or undergo health examination 
are screened while those potential patients who do not seek medical treatment are excluded 
from the screening. Therefore, some high-risk populations may be missed during the screening 
and the effectiveness of the screening is thus impaired. We can step up the publicity of 
screening programs, use information systems to manage residents’ health records, keep track 
of personal information of those who do not undergo screening, and then invite them for 
screening. By doing so, more of the target population may be covered. 
The awareness of the significance of screening on the part of patients and physicians needs 
to be improved. Adequate education and training are necessary for the success of 
opportunistic screening, which can raise the awareness of screening among patients and 
physicians, particularly the latter. Mandel et al. reported that with physicians’ consultation 
and advice, 81% of FOBT-positive patients were willing to accept subsequent colonoscopy. 
Therefore, to improve screening efficiency, it is of considerable importance to educate 
general practitioners and gastroenterologists about the importance of screening. At present, 
most of the colorectal cancer screening work is done by community physicians and other 
first-line medical staff, who often lack knowledge and training in epidemiology. Studies 
have shown that community health providers in the U.S. often base their choice of colorectal 
cancer screening programs on patients' wishes, rather than following relevant national 
screening guidelines. Therefore, education among medical practitioners about the 
importance of screening and the establishment of specialized agencies responsible for 
guidance and monitoring of colorectal cancer screening may help clinicians to implement 
and enforce screening guidelines.  
Government support is not enough. Many countries now have no comprehensive national 
statistics for colorectal cancer screening and thus can not develop a national screening 
strategy. The high cost of screening is also an important factor that reduces patients’ 
compliance. Accordingly, we call upon the attention of our society and government for 
colorectal cancer screening, strive for the support of the national basic medical insurance, 
and advocate the coverage of colorectal cancer screening by medical insurance. These efforts 
will help us to carry out large-scale screening programs for colorectal cancer to achieve early 
diagnosis and early treatment.  
7. Summary  
Natural population screening and opportunistic screening are two screening models 
currently prevalent in many countries. Although both screening programs are intended to 
reduce cancer incidence and mortality rates, they are different in many aspects, especially in 
their anti-cancer strategy. Population-based screening programs have been mainly 
conducted as a preventive policy in local regions with government support. It needs 
responsibility for the program’s implementation, such as population registration and quality 
assurance follow-up and evaluation. In this regard, natural population screening in many 
countries has not yet evolved into mature systematic screening. In contrast, opportunistic 
screening depends on individual members of a certain population requesting screening or 
their health advisors recommending screening. Although there is no conclusive evidence 
about its effectiveness, it has been implemented in clinical settings in different modes and 
holds great promise for clinical application.  
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